Abstract
A record number of 40 829 hematopoietic stem cell transplantation (HSCT) in 36 469 patients (15 765 allogeneic (43%), 20 704 autologous (57%)) were reported by 656 centers in 47 countries to the 2014 survey. Trends include: continued growth in transplant activity, more so in Eastern European countries than in the west; a continued increase in the use of haploidentical family donors (by 25%) and slower growth for unrelated donor HSCT. The use of cord blood as a stem cell source has decreased again in 2014. Main indications for HSCT were leukemias: 11 853 (33%; 96% allogeneic); lymphoid neoplasias; 20 802 (57%; 11% allogeneic); solid tumors; 1458 (4%; 3% allogeneic) and non-malignant disorders; 2203 (6%; 88% allogeneic). Changes in transplant activity include more allogeneic HSCT for AML in CR1, myeloproliferative neoplasm (MPN) and aplastic anemia and decreasing use in CLL; and more autologous HSCT for plasma cell disorders and in particular for amyloidosis. In addition, data on numbers of teams doing alternative donor transplants, allogeneic after autologous HSCT, autologous cord blood transplants are presented.
| Original language | English |
|---|---|
| Pages (from-to) | 786-792 |
| Number of pages | 7 |
| Journal | Bone Marrow Transplantation |
| Volume | 51 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Jun 1 2016 |
Fingerprint
ASJC Scopus subject areas
- Hematology
- Transplantation
Cite this
Hematopoietic stem cell transplantation in Europe 2014 : More than 40 000 transplants annually. / Passweg, Jakob; Baldomero, H.; Bader, P.; Bonini, Chiara; Cesaro, S.; Dreger, P.; Duarte, R. F.; Dufour, Carlo; Kuball, Jürgen H E; Farge-Bancel, Dominique; Gennery, Andrew; Kröger, Nicolaus; Lanza, F.; Nagler, Arnon; Sureda, Anna; Mohty, Mohamad.
In: Bone Marrow Transplantation, Vol. 51, No. 6, 01.06.2016, p. 786-792.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Hematopoietic stem cell transplantation in Europe 2014
T2 - More than 40 000 transplants annually
AU - Passweg, Jakob
AU - Baldomero, H.
AU - Bader, P.
AU - Bonini, Chiara
AU - Cesaro, S.
AU - Dreger, P.
AU - Duarte, R. F.
AU - Dufour, Carlo
AU - Kuball, Jürgen H E
AU - Farge-Bancel, Dominique
AU - Gennery, Andrew
AU - Kröger, Nicolaus
AU - Lanza, F.
AU - Nagler, Arnon
AU - Sureda, Anna
AU - Mohty, Mohamad
PY - 2016/6/1
Y1 - 2016/6/1
N2 - A record number of 40 829 hematopoietic stem cell transplantation (HSCT) in 36 469 patients (15 765 allogeneic (43%), 20 704 autologous (57%)) were reported by 656 centers in 47 countries to the 2014 survey. Trends include: continued growth in transplant activity, more so in Eastern European countries than in the west; a continued increase in the use of haploidentical family donors (by 25%) and slower growth for unrelated donor HSCT. The use of cord blood as a stem cell source has decreased again in 2014. Main indications for HSCT were leukemias: 11 853 (33%; 96% allogeneic); lymphoid neoplasias; 20 802 (57%; 11% allogeneic); solid tumors; 1458 (4%; 3% allogeneic) and non-malignant disorders; 2203 (6%; 88% allogeneic). Changes in transplant activity include more allogeneic HSCT for AML in CR1, myeloproliferative neoplasm (MPN) and aplastic anemia and decreasing use in CLL; and more autologous HSCT for plasma cell disorders and in particular for amyloidosis. In addition, data on numbers of teams doing alternative donor transplants, allogeneic after autologous HSCT, autologous cord blood transplants are presented.
AB - A record number of 40 829 hematopoietic stem cell transplantation (HSCT) in 36 469 patients (15 765 allogeneic (43%), 20 704 autologous (57%)) were reported by 656 centers in 47 countries to the 2014 survey. Trends include: continued growth in transplant activity, more so in Eastern European countries than in the west; a continued increase in the use of haploidentical family donors (by 25%) and slower growth for unrelated donor HSCT. The use of cord blood as a stem cell source has decreased again in 2014. Main indications for HSCT were leukemias: 11 853 (33%; 96% allogeneic); lymphoid neoplasias; 20 802 (57%; 11% allogeneic); solid tumors; 1458 (4%; 3% allogeneic) and non-malignant disorders; 2203 (6%; 88% allogeneic). Changes in transplant activity include more allogeneic HSCT for AML in CR1, myeloproliferative neoplasm (MPN) and aplastic anemia and decreasing use in CLL; and more autologous HSCT for plasma cell disorders and in particular for amyloidosis. In addition, data on numbers of teams doing alternative donor transplants, allogeneic after autologous HSCT, autologous cord blood transplants are presented.
UR - http://www.scopus.com/inward/record.url?scp=84959116459&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959116459&partnerID=8YFLogxK
U2 - 10.1038/bmt.2016.20
DO - 10.1038/bmt.2016.20
M3 - Article
VL - 51
SP - 786
EP - 792
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
IS - 6
ER -